EP1560564B1 - Mehrschichtiges transmucosales therapeutisches system - Google Patents

Mehrschichtiges transmucosales therapeutisches system Download PDF

Info

Publication number
EP1560564B1
EP1560564B1 EP03773702A EP03773702A EP1560564B1 EP 1560564 B1 EP1560564 B1 EP 1560564B1 EP 03773702 A EP03773702 A EP 03773702A EP 03773702 A EP03773702 A EP 03773702A EP 1560564 B1 EP1560564 B1 EP 1560564B1
Authority
EP
European Patent Office
Prior art keywords
layer
film
therapeutic system
mucoadhesive
shaped therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP03773702A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1560564A1 (de
Inventor
Markus Krumme
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTS Lohmann Therapie Systeme AG
Original Assignee
LTS Lohmann Therapie Systeme AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LTS Lohmann Therapie Systeme AG filed Critical LTS Lohmann Therapie Systeme AG
Publication of EP1560564A1 publication Critical patent/EP1560564A1/de
Application granted granted Critical
Publication of EP1560564B1 publication Critical patent/EP1560564B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Definitions

  • the invention relates to multilayer film-shaped therapeutic systems for the transmucosal administration of drugs, in particular of drugs. These systems are capable of delivering drugs in a controlled manner quickly and over a longer period of time.
  • Mucoadhesive dosage forms are known in the art, for example in the form of mucoadhesive tablets, discs or film-shaped dosage forms. Some such dosage forms are already available on the market. Mucoadhesive dosage forms are applied to the mucous membrane, in particular to the buccal mucosa (buccal and / or gingival mucosa), thereby enabling delivery of the active substance contained therein and absorption via the mucous membrane. It is advantageous that the active ingredients quickly get into the circulation and a rapid onset of action can be achieved. In particular, such dosage forms are suitable for the administration of those active ingredients which are absorbed only poorly from the gastrointestinal tract and / or which have a short plasma half-life.
  • the best known mucoadhesive dosage forms are tablets, which are built up in two layers and consist of a mucoadhesive layer, and a sustained-release backing layer (Aftab ®, Fa. Rottapharm). Efforts have been made to improve the performance of such mucoadhesive tablets, for example, by attaching drainage grooves, which are intended to allow the removal of saliva from the application site. Although such tablet systems are functional, they are perceived by the patient as unpleasant because they are relatively are thick, hard and inflexible and thereby cause a significant foreign body sensation.
  • mucoadhesive “discs” which can be formulated on the basis of lipophilic, insoluble polymer matrices and hydrophilic mucoadhesive polymers and optionally surfactants. These discs usually have a thickness of about 1 mm and therefore cause an unpleasant foreign body sensation in the mouth.
  • the proportion of the water-insoluble polymer components eg ethylcellulose, propylcellulose
  • the mucoadhesive systems thus produced have a greater thickness, and thereby the foreign body sensation is increased during the application period.
  • the greater thickness implies a decrease in drug release, as the diffusion paths become longer and the diffusion coefficients decrease.
  • a multilayer film-shaped drug carrier having a mucoadhesive layer which may contain polyvinyl alcohol or polyacrylic acid is known.
  • This film-shaped excipient has a backing layer containing hydroxypropyl cellulose and alkyl cellulose. The backing layer should not serve as a drug reservoir
  • US 2002/142036 A1 describes an active ingredient-containing multilayer film comprising mucoadhesive layers based on polyacrylic acid and methylcellulose.
  • the object underlying the invention was to provide mucoadhesive dosage forms, which do not have the disadvantages mentioned, in particular causing a foreign body sensation, insufficient drug release and too short adhesive life. Furthermore, these mucoadhesive dosage forms should on the one hand enable a rapid onset of action and, on the other hand, a continuous and controlled release of active ingredient lasting over a relatively long period of time.
  • the therapeutic systems according to the invention which are particularly suitable for the transmucosal administration of active ingredients, are composed of at least two interconnected layers. At least one of the layers contains active ingredient.
  • One of the two sides of the system according to the invention is limited by a mucoadhesive layer, which is optionally active ingredient-containing or drug-free. This mucoadhesive layer is in contact with the resorbing mucosa, eg. B. oral mucosa.
  • the mucoadhesive layer of the system is associated with a backing layer which is single-layered or multi-layered and serves as a drug reservoir.
  • a particular property of the mucoadhesive layer is that it swellable in aqueous media, but insoluble or difficult, ie slow, soluble is. Due to the insolubility or reduced solubility, the adhesive time on the mucous membrane is increased, thereby enabling a drug release over a longer period of time. Since the systems of the present invention are film-shaped, and preferably have a thickness of less than 1 mm, they do not cause a foreign body sensation and are not perceived as unpleasant by patients, thereby improving the acceptance of these dosage forms.
  • aqueous media are to be understood as meaning, in particular, physiological fluids, in particular saliva.
  • the mucoadhesive layer consists essentially of a polymer mixture, which is film-forming, swellable in aqueous media, but not or only slightly soluble in it.
  • the polymer blend comprises at least one hydrophilic, mucoadhesive polymer embedded or dispersed in a polymer matrix.
  • the mucoadhesive layer may contain active agent (s) or additives.
  • Said hydrophilic polymer or hydrophilic polymers is / are preferably selected from the group consisting of carboxyl-hydrophilic adhesive polymers, polyacrylates or polyacrylic acid derivatives (eg. Carbopol ® grades, Fa. BF Goodrich) and salts thereof, carboxymethylcellulose and salts thereof, poly (methyl vinyl ether-maleic anhydride) and its aqueous or alcoholic hydrolysates and salts (. eg Gantrez ® grades, such as Gantrez-AN, -S, -ES, -MS; Fa. ISP) comprises.
  • Said polymer matrix of the mucoadhesive layer is based essentially on hydrophilic, but in aqueous media insoluble or slowly soluble polymers.
  • This polymer or polymers is / are from the Group of polyvinyl alcohols selected.
  • Other polymers known to the person skilled in the art, which make it possible to permanently anchor the mucoadhesive layer to the adjacent backing layer in a dry state or in an aqueous environment, can also be used.
  • the mucoadhesive layer In order to ensure a permanent connection between the mucoadhesive layer and the overlying backing layer (or one of the individual layers of the backing layer, in the case of a multilayer backing layer), it is advantageous to select for the preparation of the polymer matrix of the mucoadhesive layer those base polymers which are compatible with the polymers used for the preparation of the backing layer are identical or at least chemically related. Generally, it is preferred that adjacent layers of the film-shaped system contain one or more identical or chemically related base polymers, which are preferably selected from the group of polyacrylates. In this way it can be ensured that the mucoadhesive layer remains permanently attached to the backing layer even in an aqueous environment (oral cavity) during the application period.
  • the polymers of the mucoadhesive layer are crosslinked by means of physical or / and chemical methods.
  • crosslinking the degree of solubility can be reduced without affecting the hydrophilicity.
  • adhesive duration of the system on the mucous membrane can be additionally and particularly advantageously improved.
  • Suitable crosslinking reagents and methods are known to the person skilled in the art (eg use of aluminum acetylacetonate or titanyl acetylacetonate as crosslinking agent).
  • the mucoadhesive layer may contain suitable additives for modulating the adhesive properties, which are known to the person skilled in the art.
  • the backing layer or (in the case of a multi-layered backing layer), the individual layers of the backing layer / are manufactured on the basis of polyacrylates, in particular on the basis of neutralized polymethyl methacrylates (eg. As Eudragit ® E 100, Eudragit ® NE 30 D, Plastoid ® B; Röhm Pharma). Polyacrylates which are swellable, but not soluble, in aqueous media-largely pH-independent-are particularly preferred.
  • the backing layer or at least one of the backing layer-forming layers may optionally contain one or more auxiliaries, preferably selected from the group of plasticizers, penetration enhancers, solubilizers, dyes, pigments and matrix formers. Suitable substances for this purpose are known to the person skilled in the art.
  • Suitable plasticizers are, for example, those from the group of hydrocarbons, alcohols (in particular higher alcohols such as dodecanol, undecanol, octanol), polyhydric alcohols, polyethylene glycols, triglycerides, carboxylic acids, derivatives of carboxylic acids, ethers, esters (eg diethyl phthalate, n-butyl adipate , Citric acid esters) and amines into consideration.
  • alcohols in particular higher alcohols such as dodecanol, undecanol, octanol
  • polyhydric alcohols polyethylene glycols
  • triglycerides polyethylene glycols
  • carboxylic acids carboxylic acids
  • derivatives of carboxylic acids ethers
  • esters eg diethyl phthalate, n-butyl adipate , Citric acid esters
  • amines into consideration.
  • Suitable absorption or permeation enhancers are in particular substances which are selected from the group comprising the following substances or substance classes: saturated or unsaturated fatty acids, fatty acid esters, in particular esters with methanol, ethanol or isopropanol (eg.
  • Oleic acid ethyl ester oleic acid methyl ester, methyl laurate, lauric acid ethyl ester, adipic acid methyl ester, adipic acid ethyl ester), straight-chain or branched fatty alcohols or their esters, in particular esters with acetic acid or lactic acid (eg ethyl oleate, ethyl laurate, ethyl palmitate, ethyl lactate, propyl lactate, propyl palmitate, propyl laurate, propyl oleate), polyhydric aliphatic alcohols or polyethylene glycols, sorbitan fatty acid esters and their derivatives obtainable by ethoxylation, fatty alcohol ethoxylates, polyoxyethylene fatty acid esters; Lauric acid diethanolamide, oleic diethanolamide, coconut fatty acid diethanolamide, D-alpha-tocopherol, lauric acid hexy
  • the total amount of plasticizers and permeation-improving substances can be up to about 10 wt .-%, based on the film-shaped dosage form. Particularly preferred is a content of less than 5 wt .-%, in particular less than 1 wt .-%.
  • solubilizers examples include polyhydric alcohols such as 1,2-propanediol, butanediols, glycerol, polyethylene glycol 400, tetrahydrofurfuryl alcohol, diethylene glycol monoethyl ether, diethyltoluamide and monoisopropylideneglycerol.
  • the proportion of the solubilizer (s), based on a pharmaceutical form, can be between 0.1 and 10% by weight, preferably 0.5 to 5% by weight.
  • Suitable pigments are in particular talc, titanium dioxide, iron oxides or platelet-shaped pigments.
  • the pigment content may be up to 80, preferably up to 70 wt .-%, based on the polymer content in the respective layer.
  • the film-shaped mucoadhesive systems according to the invention are composed of two layers, a mucoadhesive layer and an associated backing layer, which serves as a drug reservoir (FIG. 1).
  • the mucoadhesive layer can also be active-ingredient-containing and preferably contain the same active substance that is also contained in the backing layer. Drug delivery from the system to the mucosa is by diffusion from the layers of the system.
  • the backing layer is modified by suitable additives such that the permeation of water and the diffusion of active substance in this layer is reduced or blocked, relative to the diffusion and permeation in the mucoadhesive layer.
  • the systems are designed as multilayer and preferably comprise up to 6 individual layers, with a layer number of 2 to 4 being particularly preferred.
  • one of the surfaces of the system is formed by a mucoadhesive layer.
  • all layers contain the same active ingredient, in equal or different concentrations.
  • the multi-layered construction makes it possible to produce systems according to the invention which release an initial burst dose directly after administration and subsequently release a maintenance dose over a relatively long period of time (several hours, preferably 0.5 to 24 h) with a reduced release rate.
  • Particularly advantageous embodiments are those in which the backing layer consists of two or more layers and interconnected individual layers is constructed. In this way, the drug dose contained in the system can be increased.
  • the individual layers may contain additives which modify the solubility and the diffusion coefficient of the active substance in the respective layer. This gives a multilayer with a defined concentration gradient. This embodiment is particularly advantageous. The formation of a concentration gradient can be additionally supported by the fact that the active ingredient is contained in the individual layers in ascending or descending amounts or concentrations.
  • the backing layer or that outer layer which is located on the side of the system opposite the mucoadhesive surface and forms the outer surface there is modified by suitable additives such that the permeation of water and the diffusion of drug in this layer is reduced or blocked, relative to the diffusion and permeation in the mucoadhesive layer or in the other layers of the backing layer.
  • transmucosal system having at least a three-layered structure is obtained, having a mucoadhesive layer, at least one middle reservoir layer connected thereto, and an outer layer or boundary layer connected thereto (FIG. 2).
  • the drug diffusion - relative to the middle layer (s) - is reduced or even completely blocked.
  • the modification of the diffusion and permeation properties can in particular by variation of the pigment content and / or by admixing suitable diffusion-retarding polymeric (eg ethylcellulose, propylcellulose) or non-polymeric adjuvants.
  • suitable diffusion-retarding polymeric eg ethylcellulose, propylcellulose
  • non-polymeric adjuvants eg ethylcellulose, propylcellulose
  • the diffusion properties of the back layer and the outermost layer of the back layer between two extremes can be adjusted, namely between complete diffusion blockade on the one hand and virtually unhindered or unmodified drug diffusion from the matrix on the other.
  • systems may be prepared which release the drug (s) unilaterally (ie, only on the mucoadhesive side) or release bilaterally (ie, on the mucoadhesive side and on the opposite side of the system).
  • At least the middle layer (s) of the system is / are containing active ingredient;
  • said outer boundary layer also contains the same active substance (s).
  • the mucoadhesive layer can also be active ingredient-containing.
  • a system is obtained in which the release of active ingredient is controlled by a combination of a matrix-controlled diffusion control and a membrane-controlled release.
  • a system based on a mixed control (combination of matrix and membrane control) would release the active ingredient in a kind of saturation function, ie the release rate of the system would continue to decrease with increasing use of the system.
  • suitable formulation in particular by suitable choice of the matrix polymer (increase in the proportion of hydrophilic functional groups) or by addition of suitable hydrophilic, water-binding additives (in particular polyalcohols or polymeric surfactants with a high HLB value, preferably HLB ⁇ 10, in particular HLB ⁇ 15), can increase with Dwell time of the system in the humid medium (ie at the site of application in the oral cavity) influences and increases the degree of water absorption or the degree of swelling of the reservoir matrix.
  • suitable hydrophilic, water-binding additives in particular polyalcohols or polymeric surfactants with a high HLB value, preferably HLB ⁇ 10, in particular HLB ⁇ 15
  • the diffusion coefficient in the reservoir layer can be increased by increasing swelling or by increasing the degree of hydration. This makes it possible to compensate for the decrease in the release rate caused by the decrease in the concentration gradient by increasing swelling and hydration of the drug matrix, thereby resulting in a substantially linear release, combined with a high utilization of the system.
  • At least one of the layers of the film-shaped systems according to the invention contains an active substance or a combination of active substances.
  • the polymers of the individual layers form a polymer matrix which serves as a drug reservoir.
  • the active substance (s) is / are contained in dissolved, suspended or emulsified form, preferably "dissolved” in the sense of a "solid solution”.
  • Particularly suitable drugs are drugs, particularly preferably highly effective drugs, eg. B.
  • the systems according to the invention are particularly suitable for the administration of such drugs which are subject to rapid metabolization and / or which are only insufficiently absorbed by the gastrointestinal route.
  • the invention is explained in more detail below with reference to examples and drawings.
  • FIG. 1 and FIG. 2 show a schematic sectional view of the layer structure of two exemplary mucoadhesive systems (1) according to the invention.
  • Fig. 1 shows a system (1) having a two-layered construction comprising a mucoadhesive layer or adhesive layer (2) and a backing layer or reservoir layer (3) connected thereto.
  • the mucoadhesive layer (2) of the imaged system (1) is in adhesive contact with a mucous membrane (4); Condition during application.
  • Fig. 2 shows a system (1) having a three-layered structure comprising a mucoadhesive layer (2) and a backing layer (3) consisting of two individual reservoir layers (3a, 3b), a middle layer (3a) and a outer layer or boundary layer (3b).
  • the reservoir layer (3b) which terminates the system to the outside is preferably designed to be diffusion-controlled.
  • An active substance is in a neutral polyacrylate (for example, Eudragit ® NE 30 D;.. Rohm) either dissolved directly, or using a suitable, known to those skilled Solvent, if necessary using a solubilizer or solubilizer.
  • a neutral polyacrylate for example, Eudragit ® NE 30 D;.. Rohm
  • the active ingredient-containing polymer solution is added to a suitable pigment, for. Talc, TiO 2 , iron oxides or platelet pigments, and a homogeneous liquid.
  • the pigment content is relatively high and is about 60 wt .-%, based on the polymer content. Subsequently, the viscosity of the liquid is adjusted so that it is suitable for the subsequent processing methods.
  • the liquid is preferably applied to an inert pad by a casting or spraying method and subjected to subsequent drying, resulting in a thin film.
  • the inert pad used must be such that the film adheres to it after drying, but can be detached without destruction of the pad.
  • a second liquid is prepared, which differs from the first formulation only by the absence of the pigment or by a lower pigment content.
  • the proportion of active ingredient is increased relative to the total solids content, compared to the first produced liquid.
  • the second liquid is in turn coated by means of a spraying or casting process on the first prepared layer and subsequently dried, so that a two-layer laminate having two reservoir layers is obtained.
  • an aqueous solution of highly hydrolyzed polyvinyl alcohol for example: Mowiol 28-99, Clariant Co.
  • suitable concentration for example 10% by weight, optionally 0.5 to 60% by weight
  • an adhesive polymer eg Gantrez S 95, Fa. ISP
  • the proportion of the adhesive polymer in this example corresponds to the proportion of polyvinyl alcohol (ie mixing ratio 1: 1, parts by weight). But it can also be used other mixing ratios, for. B. in the range of 50: 1 to 1:50, based on adhesive content: polyvinyl alcohol content).
  • the homogeneous solution obtained is again coated with a suitable application method on the previously prepared two-layer laminate and then dried. This gives you a - depending on the application weight - about 50 to 250 microns thick three-layer laminate.
  • the top of this laminate is well sticky when wet and has mucoadhesive properties.
  • the laminate has an overall very good flexibility and remains after application to a mucous membrane for several hours there adhere.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP03773702A 2002-11-13 2003-11-04 Mehrschichtiges transmucosales therapeutisches system Expired - Lifetime EP1560564B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10252726 2002-11-13
DE10252726A DE10252726B4 (de) 2002-11-13 2002-11-13 Mehrschichtiges transmucosales therapeutisches System
PCT/EP2003/012272 WO2004043426A1 (de) 2002-11-13 2003-11-04 Mehrschichtiges transmucosales therapeutisches system

Publications (2)

Publication Number Publication Date
EP1560564A1 EP1560564A1 (de) 2005-08-10
EP1560564B1 true EP1560564B1 (de) 2008-01-02

Family

ID=32239998

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03773702A Expired - Lifetime EP1560564B1 (de) 2002-11-13 2003-11-04 Mehrschichtiges transmucosales therapeutisches system

Country Status (19)

Country Link
US (2) US8808729B2 (es)
EP (1) EP1560564B1 (es)
JP (1) JP4653488B2 (es)
KR (1) KR101050002B1 (es)
CN (1) CN100536834C (es)
AR (1) AR041945A1 (es)
AT (1) ATE382331T1 (es)
BR (1) BRPI0315461B8 (es)
CA (1) CA2502349C (es)
DE (2) DE10252726B4 (es)
ES (1) ES2301845T3 (es)
IL (1) IL168483A (es)
MX (1) MXPA05005023A (es)
PL (1) PL215262B1 (es)
PT (1) PT1560564E (es)
RU (1) RU2331406C2 (es)
TW (1) TWI344374B (es)
WO (1) WO2004043426A1 (es)
ZA (1) ZA200503098B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2299082T3 (es) * 2004-09-01 2008-05-16 Labtec Gesellschaft Fur Technologische Forschung Und Entwicklung Mbh Parche para cavidades.
US20080267891A1 (en) * 2007-04-30 2008-10-30 Colgate-Palmolive Company Oral Care Composition To Reduce Or Eliminate Dental Sensitivity
US20090186090A1 (en) * 2007-04-30 2009-07-23 Colgate-Palmolive Oral Care Composition to Reduce or Eliminate Dental Sensitivity
CN105833420A (zh) * 2008-06-23 2016-08-10 生物递送科学国际公司 多向粘膜给药装置及使用方法
EP2299970A2 (en) * 2008-06-30 2011-03-30 Coloplast A/S Canker sore patch
WO2010134904A1 (en) 2009-05-18 2010-11-25 Colgate-Palmolive Company Oral compositions containing polyguanidinium compounds and methods of manufacture and use thereof
US9017718B2 (en) * 2009-05-21 2015-04-28 Bionex Pharmaceuticals Llc Dual and single layer dosage forms
DE102009022915A1 (de) * 2009-05-27 2010-12-09 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit gesteuertem Wirkstofffluss
TWI499430B (zh) 2009-12-17 2015-09-11 美國棕欖公司 抗侵蝕的牙膏組成物
JP5727517B2 (ja) 2010-01-29 2015-06-03 コルゲート・パーモリブ・カンパニーＣｏｌｇａｔｅ−Ｐａｌｍｏｌｉｖｅ Ｃｏｍｐａｎｙ 敏感なエナメル質のケアのための口腔ケア製品
AU2012385956B2 (en) 2012-07-23 2017-03-30 Crayola, Llc Dissolvable films and methods of using the same
WO2015073557A1 (en) * 2013-11-13 2015-05-21 Macular Health, Llc Oral thin film formulation for reduction of vision loss from macular degeneration
EP4252779A3 (en) * 2017-06-30 2023-10-25 Allergan, Inc. Dissolving film for delivery of a clostridial derivative
KR102067330B1 (ko) * 2018-02-12 2020-01-16 김남균 구강 상처 치료용 패치
KR102067331B1 (ko) * 2018-02-12 2020-01-16 김남균 마취용 구강 패치
KR102067329B1 (ko) * 2018-02-12 2020-02-11 김남균 구내염 치료용 패치
DE102019135432A1 (de) * 2019-12-20 2021-06-24 Lts Lohmann Therapie-Systeme Ag Lösliche Rückschicht für OTF
CN111728958B (zh) * 2019-12-23 2022-02-08 力品药业(厦门)股份有限公司 一种多塞平口腔贴膜及其制备方法
KR20250051993A (ko) * 2023-10-11 2025-04-18 서울과학기술대학교 산학협력단 구강점막용 접착패치 및 이의 제조방법
PL450379A1 (pl) * 2024-11-28 2026-06-01 Uniwersytet Medyczny Im. Piastów Śląskich We Wrocławiu Mieszanina do otrzymywania nośnika stomatologicznego/periodontologicznego, sposoby otrzymywania nośnika stomatologicznego/periodontologicznego, nośnik stomatologiczny/periodontologiczny oraz zastosowanie nośnika

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5562012A (en) 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
JPS5758615A (en) * 1980-09-26 1982-04-08 Nippon Soda Co Ltd Film agnent and its preparation
JPH0830004B2 (ja) * 1983-11-14 1996-03-27 コロンビア ラボラトリーズ インコーポレイテッド 生物接着性組成物およびそれにより治療する方法
US4740365A (en) * 1984-04-09 1988-04-26 Toyo Boseki Kabushiki Kaisha Sustained-release preparation applicable to mucous membrane in oral cavity
DE3681754D1 (de) 1985-04-27 1991-11-07 Nitto Denko Corp Klebepflaster und arzneimittel fuer die mundhoehle.
JPH0729915B2 (ja) * 1986-02-01 1995-04-05 帝國製薬株式会社 シ−ト状口腔内貼付剤
US4713243A (en) 1986-06-16 1987-12-15 Johnson & Johnson Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
JPH0744940B2 (ja) * 1986-12-24 1995-05-17 ライオン株式会社 口腔貼付用基材
US4855142A (en) * 1987-02-27 1989-08-08 Ciba-Geigy Corporation Pharmaceutical plaster
US5719197A (en) 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
JPH01279838A (ja) * 1988-04-30 1989-11-10 Kiyuukiyuu Yakuhin Kogyo Kk 塩化リゾチーム含有歯肉炎・歯槽膿漏用貼付剤
US5047244A (en) * 1988-06-03 1991-09-10 Watson Laboratories, Inc. Mucoadhesive carrier for delivery of therapeutical agent
RU2191007C2 (ru) * 1996-05-24 2002-10-20 Лиганд Фармасьютикалз Инкорпорейтед Способ лечения иhcд агонистами rxr
US5800832A (en) * 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
DE19646392A1 (de) * 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
DE19652268C2 (de) * 1996-12-16 2000-06-29 Lohmann Therapie Syst Lts Arzneizubereitung für die Freisetzung von Apomorphin in der Mundhöhle
FR2762513B1 (fr) * 1997-04-23 2003-08-22 Permatec Pharma Ag Comprimes bioadhesifs
US6072100A (en) * 1998-01-28 2000-06-06 Johnson & Johnson Consumer Products, Inc. Extrudable compositions for topical or transdermal drug delivery
EP1079813B1 (en) * 1998-04-29 2005-02-09 Virotex Corporation Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
US6375963B1 (en) * 1999-06-16 2002-04-23 Michael A. Repka Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof
DE19932603A1 (de) * 1999-07-13 2001-01-25 Gruenenthal Gmbh Wirkstoffhaltiger Mehrschichtfilm aus in situ vernetzten hydrophilen Polymeren

Also Published As

Publication number Publication date
WO2004043426A1 (de) 2004-05-27
TWI344374B (en) 2011-07-01
KR101050002B1 (ko) 2011-07-19
CA2502349C (en) 2010-09-07
TW200413026A (en) 2004-08-01
US9198878B2 (en) 2015-12-01
AR041945A1 (es) 2005-06-01
BRPI0315461B8 (pt) 2021-05-25
US20140316354A1 (en) 2014-10-23
BRPI0315461B1 (pt) 2019-04-02
CN100536834C (zh) 2009-09-09
EP1560564A1 (de) 2005-08-10
JP2006510611A (ja) 2006-03-30
ES2301845T3 (es) 2008-07-01
RU2331406C2 (ru) 2008-08-20
US8808729B2 (en) 2014-08-19
IL168483A (en) 2010-12-30
AU2003282086A1 (en) 2004-06-03
DE10252726B4 (de) 2008-05-08
DE10252726A1 (de) 2004-06-03
PL215262B1 (pl) 2013-11-29
CA2502349A1 (en) 2004-05-27
KR20050075409A (ko) 2005-07-20
DE50308945D1 (de) 2008-02-14
ZA200503098B (en) 2005-12-28
BR0315461A (pt) 2005-08-23
PL376917A1 (pl) 2006-01-09
MXPA05005023A (es) 2005-10-10
US20060039957A1 (en) 2006-02-23
CN1711072A (zh) 2005-12-21
JP4653488B2 (ja) 2011-03-16
ATE382331T1 (de) 2008-01-15
RU2005114378A (ru) 2005-11-20
PT1560564E (pt) 2008-04-10

Similar Documents

Publication Publication Date Title
DE10252726B4 (de) Mehrschichtiges transmucosales therapeutisches System
DE69923675T2 (de) Pharmazeutische trägervorrichtung welche zur verabreichung von wirkstoffen an schleimhautoberflächen geeignet ist
EP1227802B1 (de) Filmförmige zubereitung zur biphasigen freisetzung pharmakologisch wirksamer oder anderer substanzen
DD274975A5 (de) Transdermales therapeutisches system
EP1904029A2 (de) Nicht-ausspuckbarer, oraler, schnell-zerfallender film für ein neuroleptikum
EP4076392B1 (de) Lösliche rückschicht für otf
WO2001001967A1 (de) Mikroreservoirsystem auf basis von polysiloxanen und ambiphilen lösemitteln
DE102018101778A1 (de) Mehrschichtiger Oraler Dünnfilm
EP1638521A1 (de) Transmukosale darreichungsform mit vreminderter schleimhautirritation
EP1971328B1 (de) Transdermales therapeutisches system für flüchtige und/oder thermolabile stoffe
DE3786199T2 (de) Artikel fuer die verabreichung pharmakologisch aktiver substanzen.
WO2004052347A1 (de) Transmucosale und transdermale arzneimittel mit verbesserter wirkstoffresorption
EP1799183B1 (de) Selbstklebende zahnfolie
EP4277595A1 (de) Mehrschichtiger oraler dünnfilm
DE60108870T2 (de) Transdermales Verabreichungssystem für die Behandlung von Harnwegserkrankungen
EP4277632B1 (de) Orale dünnfilme
DE19728279A1 (de) Ketoprofen-Pflaster mit Langzeit/Sofort-Wirkung und Verfahren zu seiner Herstellung
DE202022107070U1 (de) Mehrschichtiges Bukkales Pflaster für blutdrucksenkende Medikamente
WO2020025695A1 (de) Transdermales therapeutisches system zur abgabe von scopolamin ohne membran
EP2742931A1 (de) Topisches Arzneimittel zur Behandlung von Aphten
NZ539617A (en) Multi-layer transmucosal therapeutic system

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050506

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20070320

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: GERMAN

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 50308945

Country of ref document: DE

Date of ref document: 20080214

Kind code of ref document: P

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20080401

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20080400860

Country of ref document: GR

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)

Effective date: 20080328

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080102

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2301845

Country of ref document: ES

Kind code of ref document: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080102

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080402

REG Reference to a national code

Ref country code: IE

Ref legal event code: FD4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080102

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080102

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080102

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080102

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20081003

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080102

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20081130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080102

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20081104

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080703

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E009225

Country of ref document: HU

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RO

Payment date: 20141023

Year of fee payment: 12

Ref country code: GR

Payment date: 20141125

Year of fee payment: 12

Ref country code: SE

Payment date: 20141119

Year of fee payment: 12

Ref country code: TR

Payment date: 20141027

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20141119

Year of fee payment: 12

Ref country code: HU

Payment date: 20141119

Year of fee payment: 12

Ref country code: PT

Payment date: 20141103

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20141118

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20160504

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160602

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20151201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160504

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151104

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151105

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151201

REG Reference to a national code

Ref country code: GR

Ref legal event code: ML

Ref document number: 20080400860

Country of ref document: GR

Effective date: 20160602

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151105

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151104

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20201120

Year of fee payment: 18

Ref country code: IT

Payment date: 20201124

Year of fee payment: 18

Ref country code: FR

Payment date: 20201120

Year of fee payment: 18

Ref country code: CH

Payment date: 20201118

Year of fee payment: 18

Ref country code: AT

Payment date: 20201119

Year of fee payment: 18

Ref country code: DE

Payment date: 20201119

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20210122

Year of fee payment: 18

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 50308945

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 382331

Country of ref document: AT

Kind code of ref document: T

Effective date: 20211104

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20211104

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211130

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211130

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211104

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211104

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220601

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211104

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20230206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211105